Drug Trial Radar · NCT07747480
A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Mar 5, 2028
Study completion Mar 5, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This goal of this sub-study is to learn how safe and tolerable the study drug, aletekitug (anti-IL-18), in participants with moderately to severely active ulcerative colitis (UC). This study is the sub-study of the platform trial.
Conditions
- Colitis, Ulcerative
Interventions
AletekitugBiological
Aletekitug will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse events (AEs)Time frame: Up to 34 weeks [End of sub-study (EOSS)]
- Number of Participants with Serious AEs (SAEs)Time frame: Up to 34 weeks (EOSS)
- Number of Participants who Discontinue Study Intervention due to AEsTime frame: Up to 34 weeks (EOSS)
- Number of Participants with Clinically Significant Changes in Laboratory ReadingsTime frame: Up to 34 weeks (EOSS)
- Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to 34 weeks (EOSS)
- Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram (ECG) ReadingsTime frame: Up to 34 weeks (EOSS)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.